My article assessing the pros and cons of fluorescent quantum dots in FACS was published. Read it on BiteSize Bio.
Novo Nordisk is a publicly listed pharmaceutical company whose origins date back into the 1920s. With the headquarter in its native Denmark, the company also has international production facilities and R&D centres in several countries, affiliates in 77 countries and a workforce of well over 42,000 staff. Diabetes care has always been an intense focus in Novo Nordisk’s history. Very recently […]
It may be hard to believe but a pharmacy talk can actually be entertaining. Prof Derek Stewart made sure of that whilst conveying some important key insights of his group’s research.
Daclizumab, marketed as Zinbryta, was approved for the treatment of relapsing-remitting multiple sclerosis (MS) in the USA and Europe in summer 2016. Daclizumab has shown superior efficacy when compared to placebo and a standard treatment (AVONEX®, interferon beta-1a) and is believed to be on a par with other novel treatments. It is a once-monthly subcutaneous injection which the patient can administer themselves. This is quite convenient to […]
It is a specialist skill to write in a manner that is accepted and credible in the academic realm. To complicate matters, different scientific journals have varying styles and expectations. The acceptance of a paper for publication does not only hinge on the brilliance of the scientific work, but also on the manner in which it is conveyed – the […]
After I tweeted about my recent post about Immunium, another Twitter user made me aware of iCancer. Why? – Because the clinical trial financed through the iCancer fundraising campaign used the Ad5PTDf35-adenovirus vector which Immunicum includes as one of their treatment platforms under development.
I thought I kick off the year with an article about Immunicum, a Swedish company I stumbled across a week or so ago. As an immunologist by training I have a soft spot for companies looking to exploit the versatility and strength of our own immune system. Immunicum does just that. In their own words, they aim to create “the […]
The first time I met Beverley was when we were both helping at a conference that was organised by postgraduates for prospective research students at the University of Aberdeen in 2012 – the PhD Journey Conference, which was masterminded by Catherine MacDonald, a fellow PhD student. Thereafter, we kept loosely in touch via LinkedIn and finally met up one fine afternoon […]